5.66
-0.05 (-0.88%)
| Previous Close | 5.71 |
| Open | 5.86 |
| Volume | 4,647,819 |
| Avg. Volume (3M) | 5,259,095 |
| Market Cap | 1,691,394,304 |
| Price / Sales | 53.96 |
| Price / Book | 1.77 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,479.57% |
| Diluted EPS (TTM) | -0.560 |
| Quarterly Revenue Growth (YOY) | -57.50% |
| Total Debt/Equity (MRQ) | 6.63% |
| Current Ratio (MRQ) | 10.15 |
| Operating Cash Flow (TTM) | -78.40 M |
| Levered Free Cash Flow (TTM) | -189.06 M |
| Return on Assets (TTM) | -12.94% |
| Return on Equity (TTM) | -15.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | AbCellera Biologics Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -1.25 |
|
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.97% |
| % Held by Institutions | 44.79% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Guardian Partners Inc. | 30 Jun 2025 | 1,786,414 |
| 52 Weeks Range | ||
| Median | 7.00 (23.68%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 08 Aug 2025 | 7.00 (23.67%) | Buy | 4.25 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Oct 2025 | Announcement | AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 |
| 29 Sep 2025 | Announcement | AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 10 Sep 2025 | Announcement | AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer |
| 27 Aug 2025 | Announcement | AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 |
| 12 Aug 2025 | Announcement | AbCellera to Participate at Upcoming Investor Conferences in September |
| 07 Aug 2025 | Announcement | AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |